NuWays sets EUR 21.50 target for Eckert & Ziegler stock

Published on 10/21/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached EUR 149.30 million versus EUR 148.80 million. Eckert & Ziegler stock costs EUR 13.06 on October 21, 2026, 1.56 percent above Xetra close.

Analyst outlook and reporting date

NuWays set a EUR 21.50 target on October 19, 2026.
First-half 2026 revenue reached EUR 149.30 million versus EUR 148.80 million.
Eckert & Ziegler stock trades at EUR 13.06 at 11:07 a.m. CEST at Lang & Schwarz on October 21, 2026, 1.56 percent above the Xetra close of October 20, 2026.
The next quarterly report is scheduled for November 12, 2026.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) stock trades at EUR 13.06 at Lang & Schwarz on October 21, 2026 at 11:07 a.m. CEST, up 1.56 percent versus the Xetra close of October 20, 2026. The latest analyst update points to a EUR 21.50 target for the next 12 months, according to Borse Online on October 19, 2026.

Three milestones shape the setup

On March 26, 2026, management set full-year revenue guidance at EUR 320.00 million and adjusted EBIT guidance at EUR 80.00 million, as reported by 4investors. On August 13, 2026, the company reported first-half revenue of EUR 149.30 million, up from EUR 148.80 million, while adjusted EBIT fell to EUR 33.30 million from EUR 35.40 million.

On October 19, 2026, NuWays rated the stock Buy and set the EUR 21.50 target. The research projected third-quarter revenue of EUR 78.80 million, up 4.60 percent year over year, and adjusted EBIT of EUR 18.20 million, up 18.20 percent, according to Borse Online.

What does the target imply?

At EUR 13.06, the EUR 21.50 target lies 64.62 percent above the Lang & Schwarz price. The estimate depends on a return to adjusted EBIT growth in the third quarter and a stronger contribution from Isotope Products, while the first-half adjusted EBIT decline remains a counter-factor.

Why the Brazil agreement matters

On October 13, 2026, Eckert & Ziegler Brazil and TerThera signed a supply agreement for GMP-grade Terbium-161 for radioligand therapies in Brazil, according to Placera. The agreement expands the group's isotope offering in South America and gives the analyst thesis a concrete commercial development.

Next report date is November 12

The next quarterly financial report is scheduled for November 12, 2026, with the third quarter as its reporting period, according to Depot Navigator. That release will test whether the projected EUR 18.20 million adjusted EBIT can offset the weaker first-half operating result.

Stock trades above the Xetra close

Eckert & Ziegler develops isotope technology for medical, scientific and measurement applications, with Medical and Isotope Products as its two operating segments, according to the company's Eckert & Ziegler investor page. Its market capitalization is EUR 814.1 million as of October 21, 2026, and the 52-week range is EUR 11.91 to EUR 17.73.

The stock was trading at EUR 13.06 at Lang & Schwarz on October 21, 2026 at 11:07 a.m. CEST, 1.56 percent above the Xetra close of October 20, 2026 at EUR 12.86. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.